highly significantP < 0.001
In the WHI Estrogen + Progestin Trial, use of CEE + MPA led to a 26% increase in breast cancer risk (38 vs 30 cases per 10,000 person-years) which was highly significant in the weighted analysis (P < 0.001) [ 121 ].
In the WHI Estrogen + Progestin Trial, use of CEE + MPA led to a 26% increase in breast cancer risk (38 vs 30 cases per 10,000 person-years) which was highly significant in the weighted analysis (P < 0.001) [ 121 ].